Signal of the Day · Regulation & Policy
FDA codifies the evidence standard for a machine-learning device — three years after it started binding sponsors
A final order effective September 11, 2026 adds 21 CFR 870.2380, publishing the special controls for cardiovascular machine learning-based notification software — controls that have bound sponsors since the underlying De Novo order of August 3, 2023 and already govern ten product codes listed under 870.2380 in FDA's product classification database as of September 15. Nothing new is required today; what changed is that buyers can finally read the standard their vendors were measured against. The codified text is an unusually usable procurement yardstick: validation on a test dataset independent of training data, a minimum of three geographically diverse sites separate from training sites, subgroup performance by site and demographic group, a described ground-truth adjudication process, human-factors assessment of misinterpretation risk, and labeling that states the expected minimum performance and the subpopulations where the device may underperform. Healthcare technology leaders should put that same list to AI vendors selling software that is not a regulated device, where no one supplies those answers unless asked. (Corrected September 15; see Standards & Corrections.)